Sign up to our newsletter Subscribe

All Topics
Health Technology Assessment (HTA)
Antimicrobial Resistance (AMR)

Newsletter SignupSubscribe

Search publications, topics, authors and more

Sign up to our newsletter Subscribe

All Topics
Health Technology Assessment (HTA)
Antimicrobial Resistance (AMR)

Newsletter SignupSubscribe

Search publications, topics, authors and more

Close

Research & Publications
News & Insights
Education
Innovation Policy Prize

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:

Antimicrobial Resistance (AMR)
Biosimilars
Cell and Gene Therapies
Chronic Diseases
Combination Therapies
COVID-19 Research
Digital Health
Drug Development/R&D
Emerging Markets
EQ-5D and PROMs
Indication-Based Pricing
Health Care Systems
Health Data and Statistics
Health Technology Assessment
Precision Medicine
Prevention
Real-World Evidence
Sustainability
Use of Medicines
Value-Based Pricing
Vaccine Research

Economics of Innovation
Measuring and Valuing Outcomes
Policy, Organisation and Incentives in Health Systems
Value, Affordability and Decision Making

News & Insights

News
Events
Insights
Bulletin

Education

Education Hub
OHE Graduate School
EVIA Programme

Innovation Policy Prize

The Prize Fund
2024 Prize Fund
2022 Prize Fund

Search publications, topics, authors and more

Latest Research & Publications

Health Technology Assessment…
Measuring and Valuing Outcomes
Societal preferences

Understanding societal preferences for priority by disease severity in England & Wales

Drug Development/R&D
Economics of Innovation
Haemophilia

A Spotlight on Haemophilia Therapies

Biosimilars
Economics of Innovation
Drug Shortages

The Cost of Drug Shortages

Combination Therapies
Value, Affordability, and…

Unlocking the Value of Combination Therapies

©Tombaky - stock.adobe.com

Chronic Diseases
Value, Affordability, and…
Alzheimer's

Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding

Combination Therapies
Value, Affordability, and…

A Framework for Value-aligned Pricing of Combination Therapies

Health Technology Assessment…
Value, Affordability, and…

How Have HTA Agencies Evolved Their Methods Over Time?

Health Care Systems
Value, Affordability, and…

Socio-Economic Value of Adult Immunisation Programmes

Close

All Publications

Filter by:

Antimicrobial Resistance (AMR)

Biosimilars

Cell and Gene Therapies

Chronic Diseases

Combination Therapies

COVID-19 Research

Digital Health

Drug Development/R&D

Emerging Markets

EQ-5D and PROMs

Indication-Based Pricing

Health Care Systems

Health Data and Statistics

Health Technology Assessment

Precision Medicine

Prevention

Real-World Evidence

Sustainability

Use of Medicines

Value-Based Pricing

Vaccine Research

Economics of Innovation

Measuring and Valuing Outcomes

Policy, Organisation and Incentives in Health Systems

Value, Affordability and Decision Making
News

Events

Insights

Bulletin
Education Hub

OHE Graduate School

EVIA Programme
The Prize Fund

2024 Prize Fund

2022 Prize Fund

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

External Expert Profile

James T. Cross

Latest Publications

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

311 - ChallengesAndOpportunities_Aug2008

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Share on Mastodon

Enter your Mastodon instance URL (optional)

Powered by GDPR Cookie Compliance

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Understanding societal preferences for priority by disease severity in England & Wales

A Spotlight on Haemophilia Therapies

The Cost of Drug Shortages

Unlocking the Value of Combination Therapies

Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding

A Framework for Value-aligned Pricing of Combination Therapies

How Have HTA Agencies Evolved Their Methods Over Time?

Socio-Economic Value of Adult Immunisation Programmes

All Publications

External Expert Profile

James T. Cross

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

Challenges and Opportunities for Improving Benefit-Risk Assessment of Pharmaceuticals from an Economic Perspective